Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in Gyre Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- −2 vs. Q1 2022
- Shares held
- 8.03M
- −1.65M (−17.0%) vs. Q1 2022
- Total value
- $14.2M
- +$7.81M (+122.3%) vs. Q1 2022
- New holders
- 7
- 3 more added
- Sold out
- 9
- 17 more reduced
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting GYRE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $57.1M |
| Q1 2026 | 56 | $23.8M |
| Q4 2025 | 44 | $23.6M |
| Q3 2025 | 48 | $23.1M |
| Q2 2025 | 48 | $25.1M |
| Q1 2025 | 46 | $20.1M |
| Q4 2024 | 41 | $21.6M |
| Q3 2024 | 37 | $20.2M |
| Q2 2024 | 30 | $15.0M |
| Q1 2024 | 21 | $14.3M |
| Q4 2023 | 16 | $15.6M |
| Q3 2023 | 32 | $1.04M |
| Q2 2023 | 29 | $796.3K |
| Q1 2023 | 40 | $707.6K |
| Q4 2022 | 35 | $2.63M |
| Q3 2022 | 35 | $3.90M |
| Q2 2022 | 41 | $14.2M |
| Q1 2022 | 43 | $6.39M |
| Q4 2021 | 51 | $13.7M |
| Q3 2021 | 66 | $75.7M |
| Q2 2021 | 69 | $87.7M |
| Q1 2021 | 89 | $113.0M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding Gyre Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 51 | $0 | 0.00% | −3,031−98.3% | Reduced |
| Wells Fargo & Company | 196 | $0 | 0.00% | −284−59.2% | Reduced |
| Blue Bell Private Wealth Management, LLC | 30 | $0 | 0.00% | 00.0% | Unchanged |
| American Portfolios Advisors | 215 | $383 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 321 | $571 | 0.00% | −47−12.8% | Reduced |
| Citigroup Inc | 500 | $1.00K | 0.00% | +500 | New |
| Tower Research Capital LLC (TRC) | 1,184 | $2.00K | 0.00% | −1,991−62.7% | Reduced |
| Steward Partners Investment Advisory, LLC | 1,000 | $2.00K | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 5,500 | $9.00K | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 5,821 | $10.0K | 0.00% | −112,968−95.1% | Reduced |
| UBS Group AG | 7,682 | $14.0K | 0.00% | +7,682 | New |
| Commonwealth Equity Services, LLC | 10,000 | $17.0K | 0.00% | 00.0% | Unchanged |
| United Capital Financial Advisers, LLC | 10,000 | $18.0K | 0.00% | +10,000 | New |
| Colorado Capital Management, Inc. | 13,712 | $24.0K | 0.02% | 00.0% | Unchanged |
| Black Diamond Financial, LLC | 18,000 | $32.0K | 0.01% | 00.0% | Unchanged |
| Prudential Financial Inc | 20,400 | $36.0K | 0.00% | +20,400 | New |
| Bank of America Corp | 22,484 | $40.0K | 0.00% | −2,229−9.0% | Reduced |
| Two Sigma Advisers, LP | 23,100 | $41.0K | 0.00% | −3,900−14.4% | Reduced |
| Susquehanna International Group, LLP | 25,367 | $45.0K | 0.00% | −19,370−43.3% | Reduced |
| Barclays PLC | 30,102 | $54.0K | 0.00% | 00.0% | Unchanged |
| HSBC Holdings PLC | 32,528 | $57.0K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 32,500 | $58.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 36,555 | $65.0K | 0.00% | −26,170−41.7% | Reduced |
| Stephens Inc | 36,785 | $65.0K | 0.00% | −425−1.1% | Reduced |
| Virtu Financial LLC | 53,977 | $96.0K | 0.01% | +53,977 | New |
| Johnson & Johnson | 66,951 | $119.0K | 0.03% | 00.0% | Unchanged |
| State Street Corp | 72,599 | $129.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 75,880 | $135.0K | 0.00% | +75,880 | New |
| RBF Capital, LLC | 132,396 | $138.0K | 0.01% | 00.0% | Unchanged |
| Essex Woodlands Management, Inc. | 78,622 | $140.0K | 0.06% | 00.0% | Unchanged |
| Northern Trust Corp | 84,531 | $150.0K | 0.00% | +843+1.0% | Added |
| Kynam Capital Management, LP | 93,434 | $166.0K | 0.04% | −12,655−11.9% | Reduced |
| Goldman Sachs Group Inc | 119,144 | $212.0K | 0.00% | +1,832+1.6% | Added |
| BlackRock Inc. | 176,333 | $314.0K | 0.00% | −77,252−30.5% | Reduced |
| Bank of New York Mellon Corp | 202,146 | $360.0K | 0.00% | −14,661−6.8% | Reduced |
| Geode Capital Management, LLC | 275,265 | $489.0K | 0.00% | −23,936−8.0% | Reduced |
| Millennium Management LLC | 337,334 | $600.0K | 0.00% | −300,465−47.1% | Reduced |
| Renaissance Technologies LLC | 796,986 | $1.42M | 0.00% | −372,876−31.9% | Reduced |
| Madison Avenue Partners, LP | 1,006,300 | $1.79M | 0.37% | +1,006,300 | New |
| Vanguard Group Inc | 1,373,012 | $2.44M | 0.00% | −20,500−1.5% | Reduced |
| Nantahala Capital Management, LLC | 2,755,903 | $4.91M | 0.43% | +335,114+13.8% | Added |
| Sabby Management, LLC | 0 | $0 | 0.00% | −1,320,000−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −476,625−100.0% | Sold out |
| CSS LLC | 0 | $0 | 0.00% | −88,656−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −77,127−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −62,368−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −62,729−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −45,915−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −23,421−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |